ATE369895T1 - Modifizierte cea nucleinsäure und expressionsvektoren - Google Patents

Modifizierte cea nucleinsäure und expressionsvektoren

Info

Publication number
ATE369895T1
ATE369895T1 AT03719662T AT03719662T ATE369895T1 AT E369895 T1 ATE369895 T1 AT E369895T1 AT 03719662 T AT03719662 T AT 03719662T AT 03719662 T AT03719662 T AT 03719662T AT E369895 T1 ATE369895 T1 AT E369895T1
Authority
AT
Austria
Prior art keywords
expression vectors
modified cea
nucleic acid
nuclic acid
polypeptide
Prior art date
Application number
AT03719662T
Other languages
English (en)
Inventor
Mark Parrington
Linong Zhang
Beni Rovinski
Linda Gritz
Trish Greenhalgh
Original Assignee
Sanofi Pasteur Ltd
Therion Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd, Therion Biologics Inc filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE369895T1 publication Critical patent/ATE369895T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03719662T 2002-04-09 2003-04-09 Modifizierte cea nucleinsäure und expressionsvektoren ATE369895T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37097202P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ATE369895T1 true ATE369895T1 (de) 2007-09-15

Family

ID=35134558

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03719662T ATE369895T1 (de) 2002-04-09 2003-04-09 Modifizierte cea nucleinsäure und expressionsvektoren
AT07012168T ATE517122T1 (de) 2002-04-09 2003-04-09 Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07012168T ATE517122T1 (de) 2002-04-09 2003-04-09 Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren

Country Status (10)

Country Link
US (1) US7786278B2 (de)
EP (2) EP1864691B1 (de)
CN (1) CN1658899B (de)
AT (2) ATE369895T1 (de)
AU (1) AU2003223527B2 (de)
CY (1) CY1109926T1 (de)
DE (1) DE60315628T2 (de)
ES (1) ES2290449T3 (de)
PT (1) PT1496939E (de)
WO (1) WO2003085087A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048860A1 (en) * 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
TWI340168B (en) * 2003-05-07 2011-04-11 Tosoh Corp Method of detecting micrometastasis
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
US8933041B2 (en) 2003-11-12 2015-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services System for treating and preventing breast cancer
DK1687322T3 (en) 2003-11-12 2017-05-15 The Government Of The United States Of America Represented By The Secretary Dept Of Health And Human PATIENT CUSTOMIZED VECTORS FOR TREATMENT AND PREVENTION OF PANCREASANCES
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2170384B1 (de) 2007-07-02 2016-04-13 Etubics Corporation Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2795833T3 (es) 2015-01-09 2020-11-24 Etubics Corp Composiciones para la vacunación contra el virus del Ebola
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
EP3286213B1 (de) 2015-04-20 2021-08-04 Etubics Corporation Verfahren und zusammensetzungen für eine kombinationsimmuntherapie

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4882278A (en) 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
US4923808A (en) * 1985-03-12 1990-05-08 Genentech, Inc. Method for identifying mutants secreting high levels of heterologous proteins
US5141742A (en) 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US6013772A (en) 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
IL89102A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Vectors,compounds and methods for expression of a human adenocarcinoma antigen
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
JPH04506666A (ja) 1990-01-24 1992-11-19 バイオジェン，インコーポレイテッド ワクチンアジュバントとしてのｌｆａ―３
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
JPH05504067A (ja) 1990-02-26 1993-07-01 コモンウェルス　サイエンティフィック　アンド　インダストリアル　リサーチ　オーガナイゼイション 大腸菌及びマイコバクテリアのためのシャトルプラスミド
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
AU660981B2 (en) 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
EP0584266B1 (de) * 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CN1083524A (zh) 1992-07-06 1994-03-09 哈佛大学校长及研究员协会 作为霍乱疫苗缺失突变体
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5462871A (en) 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
ATE359370T1 (de) 1993-02-22 2007-05-15 Gen Hospital Corp Heterologe antigene in stämmen zur impfung mit lebendzellen
CN1079830C (zh) 1993-04-20 2002-02-27 索利斯治疗学公司 对受胞内传染原感染的个体进行治疗的方法和物质
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A (en) 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
EP0789774A2 (de) 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Erhöhte immunantwort durch einführen von einem zytokingen und/oder einem kostimulierenden b7-gen in einem rekombinanten virus-exprimierenden system
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0857176A1 (de) 1995-10-25 1998-08-12 Centocor B.V. VON HUMANEM EPITHELANTIGEN Ep-CAM ABGELEITETE PEPTIDE UND IHRE ANWENDUNG
JP2001520511A (ja) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
FR2746110B1 (fr) 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
CA2261990A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
WO1998004727A1 (en) * 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
AU5805798A (en) 1996-12-31 1998-07-31 Wistar Institute, The Recombinant adenoviral vector expressing antigens associated with colorectal tumors
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
CN1247788C (zh) 1997-05-13 2006-03-29 北卡罗来纳-查佩尔山大学 基于慢病毒的基因转移载体
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP2001517433A (ja) 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
US7084239B1 (en) 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US20070048860A1 (en) 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999043839A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
EP1071333A4 (de) 1998-03-20 2005-02-23 Genzyme Corp Induktion von immunität gegen tumor-autoantigene
US6171855B1 (en) 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
CA2721011A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US20040009185A1 (en) 2000-01-05 2004-01-15 Peter Emtage Enhancing the immune response to an antigen by presensitzing with an inducing agent prior to immunizing with the agent and the antigen
CN1314472A (zh) 2000-03-22 2001-09-26 上海博德基因开发有限公司 一种新的多肽——人酪氨酸酶12和编码这种多肽的多核苷酸
CN1314474A (zh) 2000-03-22 2001-09-26 上海博德基因开发有限公司 一种新的多肽——人酪氨酸酶16和编码这种多肽的多核苷酸
AU2001272932A1 (en) 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
US20030113919A1 (en) 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2003080800A2 (en) 2002-03-20 2003-10-02 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors

Also Published As

Publication number Publication date
WO2003085087A3 (en) 2003-11-27
AU2003223527A1 (en) 2003-10-20
US20070082391A1 (en) 2007-04-12
CN1658899A (zh) 2005-08-24
PT1496939E (pt) 2007-11-22
EP1496939A4 (de) 2005-11-23
ES2290449T3 (es) 2008-02-16
EP1496939A2 (de) 2005-01-19
DE60315628D1 (de) 2007-09-27
EP1864691A1 (de) 2007-12-12
WO2003085087A2 (en) 2003-10-16
CY1109926T1 (el) 2014-09-10
DE60315628T2 (de) 2008-06-05
WO2003085087A8 (en) 2005-09-15
US7786278B2 (en) 2010-08-31
EP1864691B1 (de) 2011-07-20
AU2003223527B2 (en) 2009-01-15
CN1658899B (zh) 2013-01-02
EP1496939B1 (de) 2007-08-15
ATE517122T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
CY1109926T1 (el) Τροποποιημενο νουκλεϊκο οξυ και φορεις εκφρασης cea
CY1119285T1 (el) Φορεις εμβολιου αδενοϊου χιμπατζη
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
DE60038971D1 (de) Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
NO20074906L (no) Polynukleotid som koder for et kimaert molekyl, vertcelle som uttrykker et kimaert molekyl og rekombinant vektor omfattende polynukleotidet
DK1516932T3 (da) Koppevirus med målrettet infektionsspecificitet
ATE314482T1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
EP1548032A4 (de) Kdr-peptide und diese enthaltende impfstoffe
DE60043125D1 (de) Zusammensetzungen und Verfahren für die Tumor-Behandlung
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2004092212A3 (en) Tumor antigens bfa5 for prevention and/or treatment of cancer
EP1100815A4 (de) Von protease typ ii spaltbares peptid
DE60120500D1 (de) In Knorpelgeweben stark exprimiertes Gen
DE69941273D1 (de) Zusammenstellung und Verfahren zur Diagnose von Tumoren
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
ATE506444T1 (de) Modifizierter cea/b7-vektor
WO2003095642A3 (en) Polyepitopes and mini-genes for cancer treatment
WO2005068640A3 (en) Modified ksa and uses thereof
DE69927214D1 (de) Menschliches Gen und Protein eines Magenkrebs-Antigens
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
ATE295874T1 (de) Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1496939

Country of ref document: EP